Elsevier BV

During the COVID-19 pandemic, face-to-face assessments were limited. Fortunately, older adults have access to web-technology (60%). Thus, we aimed to explore if assessing physical performance remotely is as reliable and valid as in person. At the end of the first lockdown, 15 older adults agreed to perform two similar evaluations in remote and face-to-face conditions. Functional capacities [5-repetitions Sit-to-Stand (STS); unipodal balance, 4-m walking speed (normal (NWS); fast (FWS)), 3-m Timed-Up and Go (normal (nTUG); fast (fTUG))] and muscle power and endurance were assessed. Fast walking speed was moderately reliable. Unipodal balance, NWS and nTUG were highly reliable (ICC>0.7). fTUG, STS, muscle endurance and power were extremely reliable (ICC>0.9). For absolute reliability, SEM varied from 15.54 to 5.14%. Finally, the MDC varied from 43.07 to 14.21%. Assessing functional capacities and muscle function remotely is as reliable and valid as a face-to-face assessment and should be considered as a clinical practice.

Functional decline is a major threat to independency, progressing into functional limitations and eventually leading to disability. Chronic diseases, especially cardiovascular diseases, are important determinants of functional limitations and disability. Vascular damage exits long before it is clinically manifest and can have adverse effects on health, physical and cognitive functioning. The objective was to investigate the association between non-invasive atherosclerosis measures and physical functioning in older men. Prospective cohort study. The study was conducted in the general community. 195 independently living older men. Atherosclerosis was measured by intima media thickness (CIMT) of the common carotid artery using ultrasonography and assessment for presence of atherosclerotic plaques. Physical functioning was measured by isometric handgrip strength and leg extensor strength using a hand held dynamometer, lower extremity function using the physical performance score and ability to perform activities of daily life using the modified Stanford Health Assessment Questionnaire. Linear regression analysis was performed to estimate the associations between CIMT or plaques and physical functioning. After adjustment for confounders, higher baseline CIMT was associated with lower isometric handgrip strength at follow up (βCIMT =−7.21, 95% CI[−13.64;−0.77]). No other associations were found between CIMT and physical functioning. In addition, no associations were found for the presence of plaques and physical functioning either at baseline, or at follow-up. Atherosclerosis, as measured by higher CIMT, is related to a lower isometric handgrip strength at follow-up, but no further associations with physical functioning were found in this longitudinal study among independently living older men.

The prevalence of sarcopenia on elderly maintenance hemodialysis (MHD) has been scarcely investigated. To investigate the prevalence of decreased muscle mass and strength alone or combined (true sarcopenia) in elderly patients on MHD according to different methods and cutoff limits. Additionally, we evaluated the agreement between dual energy x-ray absorptiometry (DXA) and surrogate methods for the assessment of muscle mass. Observational and cross-sectional study. Non-institutionalized 102 elderly (age > 60 years) patients on MHD. Sarcopenia was considered when the patient fit one criteria for low muscle mass assessed by DXA, bioelectrical impedance (BIA), sum of skinfold thicknesses (SKF), calf circumference and mid-arm muscle circumference (MAMC) and one for low muscle strength evaluated by handgrip dynamometer. Decreased muscle strength was found in 85% of the patients. The prevalence of decreased muscle mass varied from 4 to 73.5% and of sarcopenia (decreased muscle mass and strength combined) from 4 to 63%, depending on the method and cutoff limit applied. A small percentage of patients (2 to 15%) were classified as sarcopenic by more than one diagnostic criteria. The agreement between DXA and the surrogate methods to assess muscle mass showed better kappa coefficients with BIA (r=0.36; P<0.01) and SKF (r=0.40; P<0.01). A wide prevalence of sarcopenia is observed depending on the method and cutoff limit applied. This may limit extrapolate on to clinical practice. BIA and SKF were the surrogate methods to assess muscle mass with the best concordance with DXA in elderly MHD patients.

Selenium has a wide range of pleiotropic effects, influencing redox homeostasis, thyroid hormone metabolism, and protecting from oxidative stress and inflammation. Serum selenium levels are reduced in the older population. to investigate the association of serum selenium levels with all-cause mortality in a sample of community-dwelling older adults. Data are from the ‘Invecchiamento e Longevità nel Sirente’ (Aging and Longevity in the Sirente geographic area, ilSIRENTE) study, a prospective cohort study that collected information on individuals aged 80 years and older living in an Italian mountain community (n=347). The main outcome was risk of death after ten years of follow-up. Participants were classified according to the median value of selenium (105.3 μg/L) in two groups: high selenium and low selenium. A total of 248 deaths occurred during a 10-year follow-up. In the unadjusted model, low levels of selenium was associated with increased mortality (HR, 0.66; 95% CI 0.51-0.85). After adjusting for potential confounders the relationship remained significant (HR, 0.71; 95% CI 0.54-0.92). Low serum levels of selenium are associated with reduced survival in elderly, independently of age and other clinical and functional variables.

The effects of increased dietary protein on resistance training (RT)-induced changes in body composition and skeletal muscle fiber size are uncertain in older people. We hypothesized that the ingestion of more animal-based foods, especially eggs, to achieve a higher protein intake would enhance RT-induced changes in body composition. West Lafayette, IN. 36 older people (age 61±1 y; mean ± SEM). Subjects completed RT three d/wk for 12 weeks, and consumed omnivorous diets that contained either 0.9±0.1 (lower protein) or 1.2±0.0 (higher protein) g protein·kg−1·d−1 (12±3 and 17±5 % of energy intakes, respectively), with the higher protein intake achieved by consuming more eggs, meats, and dairy foods. The lower and higher protein diets contained 213±21 and 610±105 mg cholesterol/d, respectively. Strength, body composition, serum lipid-lipoprotein profile, urinary creatinine, skeletal muscle fiber type and size. Among all subjects, over time (i.e. with RT) body weight was unchanged, lean mass (1.1±0.2 kg) increased, and fat mass (−1.4±0.2 kg) decreased (all changes P<0.05). Regional (i.e. trunk, legs, arms) lean mass increased and fat mass decreased. Whole body muscle mass (24-h urinary creatinine excretion) increased, but skeletal muscle (vastus lateralis) type 1, type 2a, and type 2x fiber cross-sectional areas did not change from baseline. Serum total and LDL cholesterol decreased (P<0.05) and HDL cholesterol and triacylglycerol were unchanged. Dietary protein and cholesterol intakes did not influence these responses to RT. Consumption of diets that contained moderately higher protein and variable amounts of cholesterol did not differentially affect body composition, skeletal muscle fiber size, or serum lipid-lipoprotein profile responses to resistance training in older people.

While clinical endpoints provide important information on the efficacy of treatment in controlled conditions, they often are not relevant to decision makers trying to gauge the potential economic impact or value of new treatments. Therefore, it is often necessary to translate changes in cognition, function or behavior into changes in cost or other measures, which can be problematic if not conducted in a transparent manner. The Dependence Scale (DS), which measures the level of assistance a patient requires due to AD-related deficits, may provide a useful measure of the impact of AD progression in a way that is relevant to patients, providers and payers, by linking clinical endpoints to estimates of cost effectiveness or value. The aim of this analysis was to test the association of the DS to clinical endpoints and AD-related costs. The relationship between DS score and other endpoints was explored using the Predictors Study, a large, multi-center cohort of patients with probable AD followed annually for four years. Enrollment required a modified Mini-Mental State Examination (mMMS) score ≥30, equivalent to a score of approximately ≥16 on the MMSE. DS summated scores (range: 0–15) were compared to measures of cognition (MMSE), function (Blessed Dementia Rating Scale, BDRS, 0–17), behavior, extrapyramidal symptoms (EPS), and psychotic symptoms (illusions, delusions or hallucinations). Also, estimates for total cost (sum of direct medical cost, direct non-medical cost, and cost of informal caregivers’ time) were compared to DS scores. For the 172 patients in the analysis, mean baseline scores were: DS: 5.2 (SD: 2.0), MMSE: 23.0 (SD: 3.5), BDRS: 2.9 (SD: 1.3), EPS: 10.8%, behavior: 28.9% psychotic symptoms: 21.1%. After 4 years, mean scores were: DS: 8.9 (SD: 2.9), MMSE: 17.2 (SD: 4.7), BDRS: 5.2 (SD: 1.4), EPS: 37.5%, behavior: 60.0%, psychotic symptoms: 46.7%. At baseline, DS scores were significantly correlated with MMSE (r=−0.299, p<0.01), BDRS (r=0.610, p<0.01), behavior (r=.2633, p=0.0005), EPS (r=0.1910, p=0.0137) and psychotic symptoms (r=0.253, p<0.01); and at 4-year follow-up, DS scores were significantly correlated with MMSE (r=−0.3705, p=0.017), BDRS (r=0.6982, p<0.001). Correlations between DS and behavior (−0.0085, p=0.96), EPS (r=0.3824, p=0.0794), psychotic symptoms (r=0.130, ns) were not statistically significant at follow-up. DS scores were also significantly correlated with total costs at baseline (r=0.2615, p=0.0003) and follow-up (r=0.3359, p=0.0318). AD is associated with deficits in cognition, function and behavior, thus it is imperative that these constructs are assessed in trials of AD treatment. However, assessing multiple endpoints can lead to confusion for decision makers if treatments do not impact all endpoints similarly, especially if the measures are not used typically in practice. One potential method for translating these deficits into a more meaningful outcome would be to identify a separate construct, one that takes a broader view of the overall impact of the disease. Patient dependence, as measured by the DS, would appear to be a reasonable choice — it is associated with the three clinical endpoints, as well as measures of cost (medical and informal), thereby providing a bridge between measures of clinical efficacy and value in a single, transparent measure.

This study aimed to clarify the association between calorie intake and cognitive function in community-dwelling older adults. A cross-sectional analysis was performed on the first-year baseline data of 1559 adults aged 70–84 years using population data from the Korean Frailty and Aging Cohort Study. We included 543 participants who participated in nutritional surveys and accurately responded regarding their daily calorie intake. Daily ingestion was measured using the 24-hour dietary recall method, and neuropsychological tests evaluated cognitive characteristics. Logistic regression models were utilized to calculate odds ratios (ORs) with 95% confidence intervals (CIs). The prevalence rate of cognitive impairment was 8%. Subjects with cognitive impairment mainly showed memory loss. After adjusting the confounding factors, participants who had less than the recommended intake were susceptible to cognitive impairment compared to those who that had the proposed intake (adjusted OR: 7.70, 95% CI: 1.01–58.45). We showed that lesser calorie intake than the recommended intake increases the ORs of cognitive impairment. We suggest that an adequate calorie intake protects against cognitive decline, and further studies are essential to investigate the influence of calorie intake reduction on the elderly before widespread application.